RPRX
Royalty Pharma plc · Healthcare · Medical - Pharmaceuticals
Momentum inputs (comparable managers):
holder breadth -7.1% ·
share flow +7.1% ·
net new positions -7.7%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 146 | 0 | 306.62M | $17.19B | +5 | −4 |
| Q1 2026 | 148 | +6 | 297.67M | $14.26B | +10 | −5 |
| Q4 2025 | 141 | +1 | 305.31M | $11.80B | +2 | — |
| Q3 2025 | 19 | +1 | 173.40M | $6.12B | +2 | −2 |
| Q2 2025 | 16 | 0 | 158.26M | $5.71B | — | — |
| Q1 2025 | 13 | -3 | 61.13M | $1.91B | — | −3 |
| Q4 2024 | 16 | +2 | 77.30M | $1.97B | +2 | — |
| Q3 2024 | 13 | -1 | 62.78M | $1.78B | +1 | −2 |
| Q2 2024 | 14 | — | 58.59M | $1.54B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 16.12M | -1.4% | $456.11M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 16.12M | -1.4% | $456.11M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 16.12M | -1.4% | $456.11M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 16.12M | -1.4% | $456.11M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 5 | Viking Global Investors ✦ | 12.09M | +1.0% | $342.14M | 1.2% | ▲ Add | 2 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 11.90M | +8.8% | $336.63M | 0.6% | ▲ Add | 2 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 7.27M | +6.1% | $205.56M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 7.27M | +6.1% | $205.56M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 4.81M | 0.0% | $136.06M | 0.0% | Held | 2 | SEC ↗ |
| 10 | Millennium Management ✦ | 4.34M | +84.7% | $122.82M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 2.43M | +18.1% | $68.73M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 12 | Arrowstreet Capital ✦ | 1.39M | +47.9% | $39.33M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 932.34K | +2673.8% | $26.38M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 663.29K | -15.6% | $18.71M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 663.29K | -15.6% | $18.71M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 663.29K | -15.6% | $18.71M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Point72 Asset Management ✦ | 526.63K | New | $14.90M | 0.1% | New | 1 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 286.30K | +5.9% | $8.10M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | Wellington Management ✦ | 17.81K | -69.0% | $503,732 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Wellington Management ✦ | 17.81K | -69.0% | $503,732 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 21 | Wellington Management ✦ | 17.81K | -69.0% | $503,732 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $14.90M | 0.1% |
Exited
| Marshall Wace | $24.94M | was 0.0% |
| Bridgewater Associates | $6.30M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 583 holders, 354.58M shares, $16.55B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 100.00K sh · $6.00M
Officer · 9.23K sh · $540,752
Officer · 1.77K sh · $104,799
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
18.7% of class · View original SEC filing ↗
4.8% of class · View original SEC filing ↗